abemaciclib,fulvestrant,ribociclib
eli lilly,novartis
[]
 presents the ist maintain, a remarkable achievement. fulv plus ribo post cdkplusai improved pfs and orr vs fulv alone. interestingly benefit appeared limited to those with esr wt and no co-mutations. nextmonarch phase iii trial enrolling. #asco22 